levodopa and ergoline
levodopa has been researched along with ergoline in 238 studies
Research
Studies (238)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 138 (57.98) | 18.7374 |
| 1990's | 43 (18.07) | 18.2507 |
| 2000's | 41 (17.23) | 29.6817 |
| 2010's | 16 (6.72) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Schreiber, V | 1 |
| Frantz, AG; Kleinberg, DL | 1 |
| Battista, AF; Fuxe, K; Goldstein, M; Lew, JY; Lieberman, A; Nakamura, S | 1 |
| Hungerbühler, JP; Regli, F | 1 |
| Estey, E; Goldstein, M; Goodgold, A; Gopinathan, G; Kupersmith, M; Lieberman, AN | 1 |
| Carvey, PM; Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Bell, RD; Boyar, RM; Carruth, A; Rosenberg, RN | 1 |
| Heuson, JC; Rozencweig, M | 1 |
| Debono, AG; Donaldson, I; Marsden, CD; Parkes, JD | 1 |
| Calne, DB; Gielen, AC; Gillespie, MM; Kartzinel, R; Perlow, M; Sadowsky, DA; TEYCHENNE, P | 1 |
| Goldstein, M; Kleinberg, D; Kupersmith, M; Leibowitz, M; Lieberman, AN; Mehl, S; Neophytides, A; Serby, M | 1 |
| Alagna, S; Delitala, G; Devilla, L; Lotti, G; Masala, A; Rovasio, PP | 1 |
| Silvestrini, F | 1 |
| Calne, DB; Kartzinel, R; Shoulson, I | 2 |
| Castegnaro, E; Pontiroli, AE; Pozza, G; Vettaro, MP; Viberti, GC | 1 |
| Durand, JP; Gautier, JC | 1 |
| Godwin-Austen, RB; Smith, NJ | 1 |
| Estey, E; Goldstein, M; Gopinathan, G; Kupersmith, M; Lieberman, A | 1 |
| Kellams, JJ; Lemberger, L; Rowe, H; Small, JG | 1 |
| Klawans, HL; Nausieda, PA; Weiner, WJ | 1 |
| Lachelin, GC; Leblanc, H; Yen, SS | 1 |
| Fahn, S; Hutt, CS; Snider, SR | 1 |
| Jotkowitz, S | 1 |
| Delitala, G | 1 |
| Hara, I; Kageyama, N; Kataoka, K; Kuwayama, A; Nakane, T; Takanohashi, M; Tomita, A | 1 |
| Halbhübner, K; Herken, H; Loos, D | 1 |
| Boisvert, C; Roberge, AG; Roy, JP | 1 |
| Bern, SM; Calne, DB; McInturff, D; Pfeiffer, RF; Teychenne, PF | 1 |
| Klawans, HL; Kramer, J; Nausieda, PA; Wiener, WJ | 1 |
| Gerlach, J | 1 |
| Kunz, F; Lörincz, P; Ludin, HP; Ringwald, E | 1 |
| Aoki, Y; Hosogi, H; Ogawa, N; Takahara, J; Yamauchi, J | 1 |
| Calne, DB; Pfeiffer, RF; Teychenne, PF | 1 |
| Johnson, AM; Loew, DM; Vigouret, JM | 1 |
| Calne, DB; Kartznel, R | 1 |
| McLellan, DL | 1 |
| Estey, E; Goldstein, M; Kupersmith, M; Lieberman, A | 1 |
| Agnoli, A; Casacchia, M; Meco, G; Zamponi, A | 1 |
| Alagna, S; Delitala, G; Devilla, L; Lotti, G; Masala, A | 1 |
| Debono, AG; Marsden, CD; Parkes, JD | 1 |
| Cerný, V; Chmelík, V; Papez, L; Vachousek, J | 1 |
| Camanni, F; Isaia, GC; Massara, F; Molinatti, GM | 1 |
| Alagna, S; Delitala, G; Devilla, L; Masala, A | 1 |
| Camanni, F; Fassio, V; Massara, F; Molinatti, GM; Müller, EE | 1 |
| Aono, T; Sato, Y; Shioji, T; Ueda, G; Yamasaki, M | 1 |
| Close, SP; Elliott, PJ; Walsh, DM | 1 |
| Ekman, A; Eriksson, E | 1 |
| Buonamici, M; Cervini, MA; Maj, R; Mantegani, S; Rossi, AC | 1 |
| Breese, GR; Criswell, HE; Mueller, RA | 1 |
| Hofman, R; Pfeiffer, RF | 1 |
| Greiner, HE; Haase, AF; Seyfried, CA | 1 |
| Collier, TJ; Sladek, JR; Steece-Collier, K; Yurek, DM | 1 |
| Davis, A; Jenner, P; Marsden, CD | 1 |
| Di Chiara, G; Morelli, M | 1 |
| Goldstein, M; Gopinathan, G; Lieberman, AN; Pasternack, P | 1 |
| Chase, TN; Engber, TM; Kuo, S; Susel, Z | 1 |
| Dupont, E; Fabre, N; Hirt, D; Hoyer, M; Lataste, X; Lücking, C; Poewe, W; Rascol, O; Rinne, U; Teräväinen, H | 1 |
| Lera, G; Muruzabal, J; Obeso, JA; Vaamonde, J | 1 |
| Lang, AE; Lataste, X; Riley, DE; Vachon, L | 1 |
| Boyson, SJ | 1 |
| Luquin, MR; Obeso, JA; Vaamonde, J | 1 |
| Rinne, UK | 4 |
| Schneider, JS | 1 |
| Agnoli, A; Agostini, C; Barbato, L; Bragoni, M; Carta, A; Ruggieri, S; Stocchi, F | 1 |
| Boyce, S; Clarke, CE; Crossman, AR; Robertson, RG; Sambrook, MA | 1 |
| Chiodini, PG; Dallabonzana, D; Liuzzi, A; Oppizzi, G; Verde, GG | 1 |
| Harvey, NS | 1 |
| Coleman, R; Critchley, P; Grandas Perez, F; Marsden, CD; Parkes, D; Quinn, N | 1 |
| Goldstein, M; Leibowitz, M; Lieberman, AN | 1 |
| Fernandez Pardal, M; Gatto, M; Micheli, F; Perez y Gonzalez, N | 1 |
| García, S; Gershanik, OS; Scipioni, O | 1 |
| Heikkila, RE; Manzino, L; Sonsalla, PK | 1 |
| Aljanati, R; Caamaño, JL; Chouza, C; de Medina, O; Romero, S; Scaramelli, A | 1 |
| Jenner, P; Marsden, CD | 1 |
| Jellinger, K | 2 |
| Delwaide, PJ; Gonce, M | 1 |
| Agnoli, A; Antonini, A; Baronti, F; Bellantuono, P; Bravi, D; Brughitta, G; Ruggieri, S; Stocchi, F | 1 |
| Agnoli, A; Bragoni, M; Bravi, D; Carta, A; Giorgi, L; Ruggieri, S; Stocchi, F | 1 |
| Agnoli, A; Antonini, A; Bragoni, M; Carta, A; Ruggieri, SA; Stocchi, F | 1 |
| Caraceni, T; Giovannini, P; Piccolo, I; Scigliano, G; Soliveri, P; Suchy, I | 1 |
| Agnoli, A; Brughitta, G; Ruggieri, S; Stocchi, F | 1 |
| Bracco, F; Ferla, S; Giometto, B; Meneghetti, G; Schergna, E | 1 |
| Dupont, E; Jakobsen, J; Mikkelsen, B | 1 |
| Herbster, G; Koller, WC | 1 |
| Catarzi, L; Degl'Innocenti, F; Ginanneschi, A; Magnolfi, S; Marini, P | 1 |
| Montastruc, JL; Rascol, A; Rascol, O; Senard, JM | 1 |
| Klawans, HL; Paleologos, N | 1 |
| Critchley, P; Parkes, D | 1 |
| Korczyn, AD; Rabey, JM; Streifler, M; Treves, T | 1 |
| Diamond, SG; Markham, CH; Treciokas, LJ | 1 |
| Jankovic, J | 3 |
| Duvoisin, RC; Sage, JI | 1 |
| Goldstein, M; Lieberman, AN | 1 |
| Adam, AM | 1 |
| Baumeister, A; Breese, GR; Frye, GD; Mueller, RA; Napier, TC | 1 |
| Artieda, J; Luquin, MR; Martínez Lage, JM; Obeso, JA; Tuñón, T | 1 |
| Artieda, J; Lang, AE; Marsden, CD; Obeso, JA; Quinn, NP; Rothwell, JC | 1 |
| Luquin, MR; Martínez Lage, JM; Obeso, JA | 2 |
| Gopinathan, G; Lieberman, AN; Neophytides, A | 1 |
| Agid, Y; Dubois, B | 1 |
| Askenasy, JJ; Yahr, MD | 1 |
| Glantz, RH; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Baas, H; Fischer, PA; Japp, G; Schneider, E | 2 |
| Alfonsi, E; Horowski, R; Martignoni, E; Nappi, G; Sandrini, G | 1 |
| Bamji, AN; Calne, DB; Greenacre, JK; Leigh, PN; Teychenne, PF | 1 |
| Prazak, LM; Wu, CH | 1 |
| Burton, K; Calne, DB | 1 |
| Calne, DB; Plotkin, CN; Rosin, AJ; Teychenne, PF | 1 |
| Goldfine, ID; Vigneri, R | 1 |
| Ross, ED; Stewart, RM | 1 |
| Enna, SJ; Lake, CR; Teychenné, PF; Ziegler, MG | 1 |
| Goldberg, LI | 1 |
| Biesemeyer, H; Ludin, HP; Ringwald, E | 1 |
| Beckman, J; Burton, K; Calne, DB; Martin, WR | 1 |
| Glatt, S; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Calne, DB; Dambrosia, JM; Foster, N; Larsen, TA; LeWitt, PA; Newman, RP; Raphaelson, MI; Ward, CD | 1 |
| Pearce, JM | 1 |
| Da Prada, M; Haefely, WE; Keller, HH; Kettler, R; Pieri, L | 1 |
| Albizzati, MG; Bassi, S; Frattola, L; Spano, PF; Trabucchi, M | 1 |
| De Bruyne, H; Jeanty, P; Lowenthal, A; Van den Kerchove, M | 1 |
| Goldstein, M; Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Nelson, J; Neophytides, A; Walker, R | 2 |
| Agid, Y; Barroche, G; de Smet, Y; Lhermitte, F; Mear, JY; Weber, M | 1 |
| Fahn, S; Jackson-Lewis, V; Reches, A; Wagner, HR; Yablonskaya-Alter, E | 1 |
| Fischer, PA; Hubener, K; Schneider, E | 2 |
| Brincat, S; Lang, AE; Marsden, CD; Parkes, JD; Quinn, NP; Thompson, C | 1 |
| Caraceni, T; Carella, F; Giovannini, P; Grassi, MP; Parati, E; Scigliano, G | 1 |
| Diamond, SG; Markham, CH | 1 |
| Brincat, S; Lang, AE; Marsden, CD; Parkes, JD; Quinn, N | 1 |
| Gopinathan, G; Hiesiger, E; Leibowitz, M; Lieberman, AN; Neophytides, A; Walker, R | 1 |
| Agostini, L; Piccinin, GL; Piccirilli, M; Rizzo, PA | 1 |
| Cote, LJ; Fahn, S; Ilson, J; Mayeux, R; Snider, SR | 1 |
| Goldstein, M; Goodgold, A; Gopinathan, G; Leibowitz, M; Lieberman, AN; Neophytides, A; Pact, V; Walker, R | 2 |
| Glantz, RH; Glatt, SL; Goetz, CG; Klawans, HL; Tanner, CM | 1 |
| Calne, DB; Teräväinen, H | 1 |
| Goldstein, M; Kleinberg, D; Kupersmith, M; Leibowitz, M; Lieberman, A; Neophytides, A; Walker, R; Zasorin, N | 1 |
| Goldstein, M; Gopinathan, G; Leibowitz, M; Lieberman, AN; Neophytides, A; Pact, V; Walker, R | 2 |
| Klawans, HL; Tanner, CM | 1 |
| Goldstein, M; Kleinberg, D; Kupersmith, M; Leibowitz, M; Lieberman, A; Neophytides, A; Pact, V | 1 |
| Goldstein, M; Gopinathan, G; Kupersmith, M; Leibowitz, M; Lieberman, A; Mehl, S; Neophytides, A | 1 |
| Marsden, CD; Parkes, JD; Schachter, M; Sheehy, MP | 1 |
| Bentlage, C; Björklund, A; Nikkhah, G; Olsson, M | 1 |
| Asin, KE; Bednarz, L; Nikkel, A; Perner, R | 1 |
| Mark, MH; Sage, JI | 1 |
| Dawson, R; Felheim, R; Phillips, MI | 1 |
| Lera, G; Obeso, JA; Rodriguez, M; Vaamonde, J | 1 |
| Di Chiara, G; Fenu, S; Morelli, M; Pinna, A | 1 |
| Schmidt, WJ; Zadow, B | 1 |
| Goshima, Y; Misu, Y; Miyamae, T; Nakamura, S; Ueda, H; Yue, JL | 1 |
| Cole, DG; Hyman, SE; Kobierski, LA; Konradi, C | 1 |
| Ahlskog, JE; Imke, S; Lieberman, A; Maraganore, DM; Matsumoto, JY; Muenter, M; Schoenfelder, J; Wheeler, K; Wright, KF | 1 |
| Boldry, RC; Chase, TN; Kask, AM; Papa, SM | 1 |
| Ahlskog, JE; Kokmen, E; Low, PA; Nickander, KK; Petersen, RC; Tyce, GM; Uitti, RJ | 1 |
| Misu, Y; Okumura, F; Sato, K; Ueda, H | 1 |
| Blanchet, PJ; Chase, TN; de Jong, D; Metman, LV; Mouradian, MM | 1 |
| Adler, CH; Ahlskog, JE; Muenter, MD; Wright, KF | 1 |
| Bonuccelli, U; Colzi, A; Del Dotto, P; Dubini, A; Grimaldi, R; Lucetti, C; Pardini, C | 1 |
| Adler, CH; Ahlskog, JE; Hiner, BC; Hurtig, HI; Hutton, JT; Koller, WC; Lieberman, A; Morris, JL; Muenter, MD; Pahwa, R; Pfeiffer, RF; Rodnitzky, RL; Stern, MB; Waters, CH | 1 |
| Anderson, T; El-Debas, T; Findley, LJ; Marsden, CD; Steiger, MJ | 1 |
| Arai, N; Isaji, M; Itoh, F; Kojima, M; Komatsu, Y; Miyagi, M; Taya, F | 1 |
| Arai, N; Isaji, M; Kojima, M; Kuno, S; Mizuta, E | 1 |
| Bracco, F; Chouza, C; Dubini, A; Dupont, E; Gershanik, O; Grimaldi, R; Marsden, CD; Marti Masso, JF; Montastruc, JL; Orlando, N; Rinne, UK | 1 |
| Bonuccelli, U; Colzi, A; Del Dotto, P; Fariello, R; Musatti, E; Persiani, S; Strolin Benedetti, M | 1 |
| Fariello, RG | 1 |
| Marsden, CD | 1 |
| Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marsden, CD; Marti Masso, JF; Montastruc, JL; Rinne, UK | 1 |
| Blanchet, PJ | 1 |
| Montastruc, JL; Rascol, O; Senard, JM | 1 |
| LeWitt, PA | 1 |
| Agapito, C; Bhattacharya, KF; Chaudhuri, KR; Pal, S | 1 |
| Clarke, CE; Deane, KH | 1 |
| Clarke, CE; Deane, KD | 1 |
| Ichikawa, K; Kojima, M | 1 |
| Diroma, C; Fraddosio, A; Iliceto, G; Lamberti, S; Moramarco, A; Palagano, G; Zenzola, A | 1 |
| Abe, K; Kashihara, K; Manabe, Y; Murakami, T | 1 |
| Brunner, H; Friess, E; Hogl, B; Trenkwalder, C; Wetter, TC; Yassouridis, A | 1 |
| Clarke, CE; Guttman, M | 1 |
| Berardelli, A; De Pandis, MF; Modugno, N; Ruggieri, S; Stocchi, F; Thomas, A; Vacca, L; Valente, M | 1 |
| Abe, K; Hotta, K; Igarashi, K; Kasuya, F; Sakoda, S | 1 |
| Kodama, R; Kondo, T; Miwa, H; Morita, S | 1 |
| Bonuccelli, U; Del Dotto, P | 1 |
| Berger, KB; Dodel, RC; DuChane, J; Köhne-Volland, R; Machat, O; Meyer, D; Oertel, WH; Reuther, M; Siebert, U; Smala, AM; Spottke, EA | 1 |
| Inzelberg, R; Nisipeanu, P; Schechtman, E | 1 |
| Harada, H; Hashimoto, H; Kono, I; Nakagawa, M; Yoshida, T; Yoshikawa, K | 1 |
| Burkhard, PR; Flachsbart, KD; Fross, RD; Horvath, J; Kleiner-Fisman, G; Lang, AE; Lerch, R; Liaudat, S; Pache, JC; Rakowski, H; Raskoff, WJ; Stalder, H | 1 |
| Clarke, CE; Gray, R; Ives, N; Wheatley, K | 1 |
| Marras, C | 1 |
| Battaglia, A; Bracco, F; Chouza, C; Dupont, E; Gershanik, O; Marti Masso, JF; Montastruc, JL | 1 |
| Grosset, D; Grosset, K; Macphee, G; Needleman, F | 1 |
| Cassel, W; Haja, D; Körner, Y; Krüger, HP; Meindorfner, C; Möller, JC; Oertel, WH; Stiasny-Kolster, K | 1 |
| Ogawa, N; Tanaka, K | 1 |
| Ling, W; Majewska, MD; Montgomery, MA; Rawson, RA; Reiber, C; Shoptaw, S; Watson, DW | 1 |
| Goetz, CG; Poewe, W; Rascol, O; Sampaio, C | 1 |
| Comella, C; Widnell, KL | 1 |
| Arthur, K; Foley, SR; Kelly, BD | 1 |
| Ludolph, A; Odin, P; Oehlwein, C; Polzer, U; Renner, R; Schüler, P; Shing, M; Storch, A; Werner, G | 1 |
| Abe, T; Isobe, C; Kikuchi, T; Murata, T; Sato, C; Terayama, Y | 1 |
| Brusa, L; Cervellino, A; Giacomini, P; Grossi, K; Izzi, F; Marciani, MG; Pierantozzi, M; Placidi, F; Romigi, A; Stanzione, P | 1 |
| Kanzato, N; Murao, H; Nishihira, T; Takara, H | 1 |
| Benes, H; Grote, L; Happe, S; Högl, B; Kohnen, R; Mathis, J; Saletu-Zyhlarz, GM; Trenkwalder, C | 1 |
| Benes, H; Högl, B; Kohnen, R; Trenkwalder, C | 1 |
| Adeva-Bartolomé, T; Alonso-Navarro, H; Jiménez-Jiménez, FJ; Ruiz-Ezquerro, JJ | 1 |
| Bédard, PJ; Bélanger, N; Calon, F; Di Paolo, T; Dridi, M; Grégoire, L; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Dengler, R; Joppich, G; Möbes, J; Schröder, C; Stiebritz, F | 1 |
| Ferrario, JE; Gershanik, OS; Larramendy, C; Murer, MG; Saborido, MD; Taravini, IR | 1 |
| Belkhir, S; Di Paolo, T; Dridi, M; Grégoire, L; Meltzer, LT; Morissette, M; Ouattara, B; Samadi, P | 1 |
| Arai, H; Hatta, K; Hattori, N; Ishikawa, K; Kamigaichi, R; Kubo, S; Mochizuki, H; Ogaki, K; Usui, C; Yokoyama, K | 1 |
| Kulisevsky, J; Martinez-Corral, M; Pagonabarraga, J | 1 |
| Bélanger, N; Di Paolo, T; Hadj Tahar, A; Morissette, M; Samadi, P | 1 |
| Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hoyer, D; Morissette, M; Ouattara, B | 1 |
| Hornyak, M; Kohnen, R; Kriston, L; Riemann, D; Scholz, H; Trenkwalder, C | 1 |
| Di Paolo, T; Morissette, M; Parent, M; Riahi, G | 1 |
| Arbouw, ME; Egberts, TC; Guchelaar, HJ; Movig, KL; Neef, C | 1 |
| Brioschi, A; Mauro, A; Pignatti, R; Semenza, C; Wenter, J; Zamarian, L | 1 |
| Utsumi, H | 1 |
| Bini, V; Bortolato, M; Cannas, A; Marrosu, F; Puligheddu, M; Solla, P | 1 |
| George, S; Jones, HB | 1 |
| de Biase, S; Gigli, GL; Lorenzut, S; Merlino, G; Valente, M | 1 |
| Aurora, RN; Bista, SR; Casey, KR; Kristo, DA; Lamm, CI; Rosenberg, RS; Rowley, JA; Tracy, SL; Zak, RS | 1 |
| Hashida, H; Hattori, N; Iijima, M; Kano, O; Kubo, S; Matsumura, M; Murakami, H; Nanri, K; Okuma, Y; Suzuki, M; Suzuki, Y; Tomimitsu, H; Utsumi, H | 1 |
| Agúndez, JA; Alonso-Navarro, H; García-Martín, E; Jiménez-Jiménez, FJ | 1 |
| Beuthien-Baumann, B; Grählert, X; Herting, B; Kotzerke, J; Löhle, M; Oehme, L; Perick, M; Reichmann, H; Schwanebeck, U; Storch, A; van den Hoff, J; Wolz, M | 1 |
| Hisanaga, R; Nakamura, M; Nomoto, S; Sato, T | 1 |
| Ikeda, S; Ishizaki, T; Nakaoka, S; Nakayama, T; Satoh, T; Urushihara, H; Yamamoto, M | 1 |
Reviews
28 review(s) available for levodopa and ergoline
| Article | Year |
|---|---|
[Considerations in the drug treatment of parkinsonism (author's transl)].
Topics: Amantadine; Apomorphine; Bromocriptine; Dopamine; Ergolines; Extrapyramidal Tracts; Female; Humans; Levodopa; Male; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Parkinson Disease; Phosphodiesterase Inhibitors; Piribedil; Tremor | 1978 |
Medical treatment of pituitary adenomas: effects on tumor growth.
Topics: Adenoma; Adrenocorticotropic Hormone; Bromocriptine; Dihydroergotoxine; Dopamine; Drug Administration Schedule; Ergolines; Growth Hormone; Levodopa; Lisuride; Metergoline; Methysergide; Pergolide; Pituitary Neoplasms; Prolactin; Tomography, X-Ray Computed | 1985 |
Psychiatric disorders in parkinsonism: 2. Organic cerebral states and drug reactions.
Topics: Amantadine; Antiparkinson Agents; Atrophy; Brain; Bromocriptine; Cognition; Dementia; Dreams; Drug Interactions; Ergolines; Humans; Levodopa; Libido; Memory; Parasympatholytics; Parkinson Disease; Receptors, Dopamine; Sexual Behavior; Substance-Related Disorders; Visual Perception | 1986 |
The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine; Ergolines; Humans; Levodopa; Macaca mulatta; Neural Pathways; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Quinpirole; Rats; Saimiri; Selegiline; Species Specificity; Substantia Nigra | 1986 |
Long-term use of dopamine agonists in Parkinson's disease.
Topics: Bromocriptine; Corpus Striatum; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Movement Disorders; Parkinson Disease; Pergolide; Receptors, Dopamine; Time Factors | 1985 |
Bromocriptine in Parkinson disease.
Topics: Aged; Animals; Bromocriptine; Drug Administration Schedule; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1985 |
Endocrine basis for ovulation induction.
Topics: Adrenal Cortex Hormones; Bromine; Chorionic Gonadotropin; Clomiphene; Corpus Luteum; Ergolines; Estrogens; Female; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Hypothalamo-Hypophyseal System; Infertility, Female; Levodopa; Luteinizing Hormone; Menotropins; Ovary; Ovulation; Progesterone | 1974 |
Pharmacologic therapy of patients with pituitary tumors secreting prolactin, growth hormone and adrenocorticotropin.
Topics: Adrenergic alpha-Antagonists; Adrenocorticotropic Hormone; Amenorrhea; Antineoplastic Agents; Bromocriptine; Cyproheptadine; Ergolines; Estrogens; Female; Galactorrhea; Growth Hormone; Humans; Hypothalamus; Levodopa; Pituitary Gland; Pituitary Neoplasms; Pregnancy; Prolactin | 1980 |
Dopamine receptors and hypertension. Physiologic and pharmacologic implications.
Topics: Animals; Benzazepines; Blood Pressure; Bromocriptine; Domperidone; Dopamine; Ergolines; Fenoldopam; Humans; Hypertension; Levodopa; Quinpirole; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Vasoconstriction; Vasodilation | 1984 |
The pharmacology of Parkinson's disease: basic aspects and recent advances.
Topics: Animals; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Brain; Bromocriptine; Carbidopa; Corpus Striatum; Dopamine; Ergolines; Humans; Kidney; Kinetics; Levodopa; Lisuride; Liver; Methyldopa; Norepinephrine; Parkinson Disease; Pergolide; Receptors, Dopamine; Selegiline; Serotonin; Stereotyped Behavior; Substantia Nigra; Tyramine | 1984 |
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Area Under Curve; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1998 |
Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Randomized Controlled Trials as Topic | 1998 |
Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives.
Topics: Animals; Antiparkinson Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease | 1999 |
Treatment of Parkinson's disease should begin with a dopamine agonist.
Topics: Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Indoles; Levodopa; Lisuride; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D2; Thiazoles | 1999 |
New drugs for the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Benzophenones; Benzothiazoles; Cabergoline; Catechol O-Methyltransferase Inhibitors; Dopamine Agonists; Drug Synergism; Enzyme Inhibitors; Ergolines; Humans; Indoles; Levodopa; Nitrophenols; Parkinson Disease; Pramipexole; Thiazoles; Tolcapone | 2000 |
Cabergoline for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic | 2001 |
[Pharmacological effects of cabergoline against parkinsonism].
Topics: Animals; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Haplorhini; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 2001 |
DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Topics: Benzophenones; Bromocriptine; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Nitrophenols; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Tolcapone | 2002 |
Dopamine agonist monotherapy in Parkinson's disease.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2002 |
Clinical pharmacokinetics of cabergoline.
Topics: Age Factors; Antiparkinson Agents; Cabergoline; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Ergolines; Female; Food-Drug Interactions; Humans; Kidney Diseases; Levodopa; Liver Diseases; Male; Selegiline; Sex Factors | 2003 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
Topics: Amantadine; Antiparkinson Agents; Apomorphine; Benzophenones; Benzothiazoles; Bromocriptine; Cabergoline; Catechol O-Methyltransferase Inhibitors; Deep Brain Stimulation; Dihydroergocryptine; Ergolines; Fetal Tissue Transplantation; Globus Pallidus; Humans; Indans; Indoles; Levodopa; Lisuride; Mesencephalon; Monoamine Oxidase Inhibitors; Neurosurgical Procedures; Nitrophenols; Parkinson Disease; Pergolide; Piribedil; Pramipexole; Selegiline; Thiazoles; Tolcapone | 2005 |
Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Topics: Apomorphine; Benzophenones; Cabergoline; Catechol O-Methyltransferase Inhibitors; Catechols; Dopamine Agonists; Ergolines; Humans; Levodopa; Movement Disorders; Nitriles; Nitrophenols; Parkinson Disease; Tolcapone | 2005 |
Dopamine agonists for restless legs syndrome.
Topics: Benzothiazoles; Cabergoline; Dopamine Agonists; Ergolines; Humans; Levodopa; Pergolide; Pramipexole; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Severity of Illness Index | 2011 |
ADMET considerations for restless leg syndrome drug treatments.
Topics: Amines; Anticonvulsants; Benzothiazoles; Carbamates; Cyclohexanecarboxylic Acids; Dopamine Agents; Dopamine Agonists; Ergolines; Gabapentin; gamma-Aminobutyric Acid; Humans; Indoles; Levodopa; Neuralgia; Pramipexole; Pregabalin; Randomized Controlled Trials as Topic; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes; Treatment Outcome | 2012 |
The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.
Topics: Academies and Institutes; Benzothiazoles; Cabergoline; Carbamates; Dopamine Agents; Ergolines; Evidence-Based Medicine; gamma-Aminobutyric Acid; Humans; Indoles; Levodopa; Nocturnal Myoclonus Syndrome; Pergolide; Peripheral Nervous System Diseases; Pramipexole; Restless Legs Syndrome; Sleep Medicine Specialty; United States; Venous Insufficiency | 2012 |
Anti-Parkinson's disease drugs and pharmacogenetic considerations.
Topics: Aryl Hydrocarbon Hydroxylases; Benzothiazoles; Benztropine; Bromocriptine; Cabergoline; Catechols; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Ergolines; Genetic Markers; Humans; Indans; Indoles; Levodopa; Lisuride; Nitriles; Parkinson Disease; Pergolide; Pharmacogenetics; Pramipexole; Receptors, Dopamine D2; Receptors, Dopamine D3; Reproducibility of Results; Selegiline | 2013 |
Trials
47 trial(s) available for levodopa and ergoline
| Article | Year |
|---|---|
Letter: Bromocriptine in parkinsonism.
Topics: Bromocriptine; Drug Evaluation; Ergolines; Humans; Levodopa; Parkinson Disease | 1975 |
Bromocriptine and levodopa (with or without carbidopa) in parkinsonism.
Topics: Aged; Bromocriptine; Carbidopa; Clinical Trials as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Ergolines; Female; Follow-Up Studies; Humans; Hydrazines; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Time Factors | 1976 |
Pergolide and lisuride for Parkinson's disease.
Topics: Antiparkinson Agents; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease | 1979 |
An ergot derivative in the treatment of Parkinson's disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Bromocriptine; Clinical Trials as Topic; Ergolines; Humans; Levodopa; Parkinson Disease | 1976 |
Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine.
Topics: Administration, Oral; Adolescent; Adult; Benserazide; Bromocriptine; Clinical Trials as Topic; Drug Interactions; Ergolines; Female; Humans; Hydrazines; Levodopa; Male; Metergoline; Methysergide; Middle Aged; Pituitary Gland; Pituitary Gland, Anterior; Prolactin; Secretory Rate; Stimulation, Chemical; Time Factors | 1977 |
[Treatment of parkinsonian syndromes by bromocriptin].
Topics: Aged; Amantadine; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Hypotension; Levodopa; Male; Movement Disorders; Nausea; Parkinson Disease, Secondary | 1977 |
Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Humans; Individuality; Levodopa; Male; Middle Aged; Parkinson Disease | 1977 |
Treatment of Parkinson's disease with lergotrile mesylate.
Topics: Acetonitriles; Antiparkinson Agents; Bromocriptine; Carbidopa; Carboxy-Lyases; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Parkinson Disease | 1977 |
Effect of CB 154 (2-bromo-alpha-ergocryptine) on paralysis agitans compared with Madopar in a double-blind, cross-over trial.
Topics: Aged; Azides; Benserazide; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Combinations; Ergolines; Female; Humans; Hydrazines; Hyperkinesis; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1976 |
Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Drug Evaluation; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Tremor | 1976 |
[Clinical experience with bromocriptine, a central dopaminergic stimulator].
Topics: Aged; Amantadine; Bromocriptine; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Placebos; Trihexyphenidyl | 1976 |
CQA 206-291 in Parkinson's disease.
Topics: Activities of Daily Living; Aged; Dopamine Agents; Double-Blind Method; Drug Interactions; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease | 1991 |
Mesulergine: a dopamine agonist with novel properties in Parkinson's disease.
Topics: Aged; Dopamine Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease | 1990 |
CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1990 |
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease.
Topics: Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1989 |
A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease.
Topics: Administration, Oral; Benserazide; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Ergolines; Humans; Hydrazines; Infusion Pumps; Levodopa; Lisuride; Parkinson Disease; Severity of Illness Index | 1988 |
Therapeutic effect of lisuride in advanced Parkinson's disease.
Topics: Aged; Clinical Trials as Topic; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Time Factors | 1986 |
Mesulergine in early Parkinson's disease: a double blind controlled trial.
Topics: Aged; Antiparkinson Agents; Benserazide; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Random Allocation | 1986 |
Double-blind trial of pergolide for Parkinson's disease.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1985 |
Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Ergolines; Gait; Humans; Levodopa; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Pergolide; Random Allocation | 1985 |
Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.
Topics: Adult; Aged; Blood Pressure; Bromocriptine; Drug Administration Schedule; Ergolines; Female; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time Factors | 1985 |
Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1982 |
Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
Topics: Adult; Aged; Antiparkinson Agents; Bulbar Palsy, Progressive; Clinical Trials as Topic; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Placebos | 1983 |
A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease.
Topics: Clinical Trials as Topic; Disability Evaluation; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Pergolide; Sleep; Time Factors | 1983 |
Comparison of pergolide and bromocriptine therapy in parkinsonism.
Topics: Aged; Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1983 |
Pergolide in late-stage Parkinson disease.
Topics: Bromocriptine; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Sleep Wake Disorders | 1982 |
Assessment of hypokinesia in Parkinsonism.
Topics: Adult; Aged; Bromocriptine; Clinical Trials as Topic; Ergolines; Humans; Levodopa; Lisuride; Male; Middle Aged; Motor Activity; Movement; Parkinson Disease; Placebos; Posture; Time Factors | 1981 |
Lisuride in Parkinson disease: efficacy of lisuride compared to levodopa.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1981 |
Lisuride combined with levodopa in advanced Parkinson disease.
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1981 |
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agents; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Receptors, Dopamine | 1993 |
Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Carbidopa; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Receptors, Dopamine D1; Receptors, Dopamine D2; Treatment Outcome | 1996 |
Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1996 |
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Cabergoline; Dopamine Agonists; Double-Blind Method; Drug Administration Schedule; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Patient Dropouts; Placebos; Treatment Outcome | 1996 |
Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations.
Topics: Adult; Aged; Blood Pressure; Cabergoline; Dose-Response Relationship, Drug; Double-Blind Method; Ergolines; Humans; Levodopa; Middle Aged; Movement; Parkinson Disease; Placebos; Severity of Illness Index; Time Factors | 1996 |
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
Topics: Aged; Antiparkinson Agents; Cabergoline; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1997 |
Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease | 1997 |
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Topics: Activities of Daily Living; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1998 |
Combination of two different dopamine agonists in the management of Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Prospective Studies; Thiazoles; Treatment Outcome | 2002 |
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.
Topics: Age of Onset; Benzothiazoles; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Evidence-Based Medicine; Humans; Indoles; Levodopa; Parkinson Disease; Pramipexole; Thiazoles | 2003 |
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Case-Control Studies; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Risk Factors; Time Factors; Treatment Outcome | 2004 |
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST).
Topics: Adult; Cabergoline; Carbidopa; Cocaine-Related Disorders; Dopamine Agents; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Pilot Projects | 2005 |
Efficacy and safety of high-dose cabergoline in Parkinson's disease.
Topics: Adolescent; Adult; Aged; Amantadine; Antiparkinson Agents; Cabergoline; Catechols; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Humans; Levodopa; Middle Aged; Nitriles; Parkinson Disease; Piperidines; Prospective Studies; Quality of Life; Selegiline; Severity of Illness Index; Treatment Outcome | 2006 |
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Ergolines; Europe; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Restless Legs Syndrome | 2007 |
Augmentation in restless legs syndrome is associated with low ferritin.
Topics: Adult; Cabergoline; Dopamine Agonists; Double-Blind Method; Ergolines; Female; Ferritins; Humans; Levodopa; Male; Patient Dropouts; Prospective Studies; Restless Legs Syndrome; Retrospective Studies; Risk Factors | 2008 |
Long-term effects of cabergoline and levodopa in Japanese patients with early Parkinson's disease: a 5-year prospective study.
Topics: Adult; Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time; Treatment Outcome | 2012 |
Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Dopamine Agonists; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2013 |
Effects of dopaminergic treatment on striatal dopamine turnover in de novo Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cabergoline; Corpus Striatum; Dopamine; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Single-Blind Method; Treatment Outcome | 2013 |
Other Studies
164 other study(ies) available for levodopa and ergoline
| Article | Year |
|---|---|
[Dopaminergic neurons in the hypothalamo-hypophyseal system (IV): endocrinologic aspects of endogenous euphorigens].
Topics: Analgesics, Opioid; Antipsychotic Agents; Apomorphine; Dopamine; Endorphins; Enkephalins; Ergolines; Hallucinogens; Humans; Hypothalamo-Hypophyseal System; Levodopa; Neurons; Pituitary Hormones, Anterior; Serotonin | 1977 |
The pathophysiology of hyperprolactinemic states and the role of newer ergot compounds in their treatment.
Topics: Acetonitriles; Amenorrhea; Bromocriptine; Dopamine; Ergolines; Ergot Alkaloids; Female; Galactorrhea; Humans; Levodopa; Pituitary Neoplasms; Pregnancy; Prolactin; Prolactin Release-Inhibiting Factors | 1978 |
Dopaminephilic properties of ergot alkaloids.
Topics: Acetonitriles; Animals; Bromocriptine; Corpus Striatum; Ergolines; Ergot Alkaloids; Haplorhini; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine; Spiperone; Substantia Nigra; Synaptosomes; Tremor; Tyrosine 3-Monooxygenase | 1978 |
Lergotrile in Parkinson disease: further studies.
Topics: Aged; Bromocriptine; Chemical Phenomena; Chemistry; Dopa Decarboxylase; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease | 1979 |
Dopaminergic antagonism of L-5-hydroxytryptophan-induced myoclonic jumping behavior.
Topics: 5-Hydroxytryptophan; Animals; Apomorphine; Dopamine Antagonists; Ergolines; Guinea Pigs; Haloperidol; Humans; Levodopa; Male; Motor Activity; Myoclonus; Receptors, Dopamine; Stereotyped Behavior; Tetrahydronaphthalenes | 1979 |
Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Circadian Rhythm; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prolactin; Sleep | 1978 |
Letter: Prolactin, levodopa, and migraine.
Topics: Bromocriptine; Ergolines; Humans; Levodopa; Migraine Disorders; Prolactin | 1975 |
Dynamic evaluation of prolactin secretion in patients with oligospermia: effects of treatment with metergoline.
Topics: Adult; Ergolines; Female; Humans; Levodopa; Male; Metergoline; Metoclopramide; Oligospermia; Pregnancy; Prolactin; Pyridoxine; Thyrotropin-Releasing Hormone | 1979 |
[Acromegaly. Recent physiopathological and therapeutic acquisitions].
Topics: Acromegaly; Ergolines; Glucose; Growth Hormone; Humans; Insulin; Levodopa; Pituitary Gland, Anterior; Somatostatin; Thyrotropin-Releasing Hormone | 1979 |
The effect of L-dopa and lergotrile mesylate on the interaction of fluphenazine decanoate and amphetamine-induced stereotypy and mortality.
Topics: Acetonitriles; Amphetamine; Animals; Behavior; Bromocriptine; Dopamine Antagonists; Drug Interactions; Ergolines; Fluphenazine; Humans; Levodopa; Male; Rats; Stereotyped Behavior | 1977 |
The effect of levodopa, lergotrile, and bromocriptine on brain iron, manganese, and copper.
Topics: Acetonitriles; Animals; Brain Chemistry; Bromocriptine; Copper; Ergolines; Guinea Pigs; Iron; Levodopa; Male; Manganese; Metals | 1978 |
The inhibitory effect of dopamine agonists on LH release in women.
Topics: Amenorrhea; Bromocriptine; Ergolines; Female; Follicle Stimulating Hormone; Humans; Levodopa; Luteinizing Hormone; Prolactin | 1977 |
Interaction between bromocriptine and levodopa. Biochemical basis for an improved treatment for parkinsonism.
Topics: Animals; Brain; Bromocriptine; Carbidopa; Dopamine; Drug Interactions; Ergolines; gamma-Aminobutyric Acid; Hydroxyindoleacetic Acid; Levodopa; Male; Parkinson Disease; Rats; Serotonin | 1977 |
Treatment of Parkinson's disease with bromocriptine.
Topics: Bromocriptine; Ergolines; Humans; Levodopa; Parkinson Disease | 1977 |
Stimulating action of sulpiride and pimozide on prolactin release. Effect on bromocriptine, L-dopa and metergoline administration.
Topics: Adolescent; Adult; Bromocriptine; Ergolines; Female; Humans; Levodopa; Male; Metergoline; Pimozide; Prolactin; Sulpiride | 1977 |
[The correlationship between basal prolactin levels and the suppressive effect of CB-154 or L-DOPA on GH release in acromegalic patients (author's transl)].
Topics: Acromegaly; Adult; Ergolines; Female; Galactorrhea; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Pregnancy; Prolactin | 1979 |
Lisuride, a potent drug in the treatment of muscular rigisity in rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Ergolines; Levodopa; Male; Muscle Rigidity; Rats; Urea | 1977 |
Effect of metergoline on delayed response in cats and its relation to the metabolism of dopamine and serotonin in neostriatal and mesolimbic neurons.
Topics: Animals; Cats; Corpus Striatum; Dopamine; Ergolines; Female; Frontal Lobe; Hypothalamus; Levodopa; Limbic System; Male; Medulla Oblongata; Mesencephalon; Metergoline; Neurons; Norepinephrine; Pons; Raphe Nuclei; Reaction Time; Septum Pellucidum; Serotonin; Thalamus | 1978 |
Comparison between lergotrile and bromocriptine in parkinsonism.
Topics: Acetonitriles; Adult; Aged; Bromocriptine; Carbidopa; Chemical Phenomena; Chemistry; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1978 |
Paradoxial response to dopaminergic agents in parkinsonism.
Topics: Acetonitriles; Aged; Carbidopa; Ergolines; Homovanillic Acid; Humans; Hydrazines; Levodopa; Male; Parkinson Disease; Receptors, Dopamine | 1978 |
[Comparison with growth hormone responses to various drugs or substances in patients with active acromegaly (author's transl)].
Topics: Acromegaly; Adult; Aged; Ergolines; Female; Glucagon; Gonadotropin-Releasing Hormone; Growth Hormone; Humans; Levodopa; Male; Middle Aged; Thyrotropin-Releasing Hormone | 1975 |
Treatment of parkinsonism.
Topics: Aromatic Amino Acid Decarboxylase Inhibitors; Bromocriptine; Carbidopa; Dopamine; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1977 |
Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.
Topics: Amphetamine; Animals; Apomorphine; Bromocriptine; Drug Interactions; Ergolines; Humans; Hydroxydopamines; Levodopa; Male; Mice; Motor Activity; Rats; Receptors, Drug; Reserpine; Stereotyped Behavior; Substantia Nigra | 1976 |
Studies with bromocriptine. Part 1. "On-off" phenomena.
Topics: Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
Comparison of reflex effects of levodopa and bromocriptine in Parkinsonism.
Topics: Bromocriptine; Ergolines; Humans; Levodopa; Parkinson Disease; Reflex | 1976 |
Treatment of parkinson's disease with bromocriptine.
Topics: Aged; Bromocriptine; Delusions; Dopa Decarboxylase; Drug Evaluation; Ergolines; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Parkinson Disease | 1976 |
[CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
Topics: Aged; Carboxy-Lyases; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1976 |
Growth hormone and prolactin release in acromegalic patients following metergoline administration.
Topics: Acromegaly; Adult; Animals; Bromocriptine; Ergolines; Growth Hormone; Humans; Levodopa; Male; Metergoline; Middle Aged; Prolactin; Serotonin; Serotonin Antagonists | 1976 |
Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
Topics: Aged; Bromocriptine; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Follow-Up Studies; Growth Hormone; Humans; Levodopa; Male; Metoclopramide; Middle Aged; Parkinson Disease; Receptors, Dopamine | 1976 |
[New possibilities of the lactation-arrest in puerperium (author's transl)].
Topics: Ergolines; Ergot Alkaloids; Female; Humans; Lactation; Levodopa; Maleates; Postpartum Period; Pregnancy; Stilbenes | 1975 |
Dopaminergic control of growth hormone secretion in normal and acromegalic subjects.
Topics: Acromegaly; Amantadine; Bromocriptine; Ergolines; Growth Hormone; Humans; Hypothalamo-Hypophyseal System; Levodopa; Phentolamine; Pituitary Gland; Propranolol | 1975 |
Metaclopramide and prolactin secretion in man: effects of pretreatment with L-dopa and 2-bromo-alpha-ergocryptine (CB-154).
Topics: Adult; Bromocriptine; Ergolines; Female; Humans; Hypothalamus; Levodopa; Male; Metoclopramide; Pituitary Gland; Prolactin | 1975 |
Effect of five dopaminergic drugs on plasma growth hormone levels in acromegalic subjects.
Topics: Acromegaly; Adult; Aged; Amantadine; Bromocriptine; Ergolines; Female; Growth Hormone; Humans; Levodopa; Male; Memantine; Middle Aged; Piperazines; Piribedil | 1975 |
Effects of CB-154 (2-Br-alpha-ergocryptine) on prolactin and growth hormone release in an acromegalic patient with galactorrhea.
Topics: Acromegaly; Ergolines; Female; Galactorrhea; Growth Hormone; Humans; Lactation Disorders; Levodopa; Pregnancy; Prolactin | 1975 |
Dopamine D1 and D2 receptor interactions in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Callithrix; Dopamine Agents; Ergolines; Female; Levodopa; Male; Movement; Parkinson Disease, Secondary; Quinpirole; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1992 |
Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the prolactin suppression induced by a series of full and partial dopamine D2 receptor agonists in male rats.
Topics: 4-Butyrolactone; Adrenergic alpha-Antagonists; Animals; Apomorphine; Dopamine Agents; Ergolines; Levodopa; Male; Piperidines; Prolactin; Quinolines; Rats; Rats, Sprague-Dawley | 1992 |
A new dopamine agonist in dopamine deprived systems: FCE 23884.
Topics: Animals; Apomorphine; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Levodopa; Male; Mice; Motor Activity; Reserpine; Time Factors | 1992 |
Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors.
Topics: Animals; Animals, Newborn; Benzazepines; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Female; Levodopa; Motor Activity; Oxidopamine; Papaverine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Self Mutilation; Sympathectomy, Chemical; Tetrahydroisoquinolines | 1992 |
Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist.
Topics: Animals; Biogenic Amines; Brain; Clonidine; Corpus Striatum; Dopamine; Dopamine Agents; Drug Interactions; Ergolines; Heart; Hypothalamus; Indoles; Levodopa; Male; Motor Activity; Norepinephrine; Oxidopamine; Pyridines; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Reserpine; Sulpiride | 1991 |
Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Brain Tissue Transplantation; Dopamine; Dopamine Agents; Dopamine Antagonists; Ergolines; Female; Fetal Tissue Transplantation; Levodopa; Male; Mesencephalon; Oxidopamine; Pregnancy; Quinpirole; Rats; Rats, Inbred F344; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Stereotyped Behavior; Sympathectomy, Chemical | 1991 |
Differential ability of selective and non-selective dopamine agonists to induce climbing in the rat indicates the involvement of both D-1 and D-2 receptors in this behaviour.
Topics: Amphetamine; Animals; Apomorphine; Benzazepines; Bromocriptine; Clonidine; Dopamine Agents; Ergolines; Female; Levodopa; Motor Activity; Pergolide; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Sulpiride | 1990 |
MK-801 potentiates dopaminergic D1 but reduces D2 responses in the 6-hydroxydopamine model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benserazide; Dizocilpine Maleate; Dopamine Agents; Ergolines; Hydroxydopamines; Levodopa; Male; Medial Forebrain Bundle; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereoisomerism; Stereotyped Behavior | 1990 |
Chronic levodopa treatment alters basal and dopamine agonist-stimulated cerebral glucose utilization.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autoradiography; Basal Ganglia; Brain; Carbon Radioisotopes; Deoxyglucose; Dopamine Agents; Dose-Response Relationship, Drug; Ergolines; Glucose; Levodopa; Male; Neural Pathways; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Thalamus | 1990 |
Cabergoline: a long-acting dopamine agonist in Parkinson's disease.
Topics: Administration, Oral; Antiparkinson Agents; Cabergoline; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine | 1990 |
CQA 206-291 in Parkinson's disease: an acute single escalating dosage study.
Topics: Aged; Antiparkinson Agents; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance | 1990 |
Treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Carbidopa; Drug Combinations; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease | 1990 |
Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Topics: Administration, Oral; Adult; Aged; Apomorphine; Drug Tolerance; Ergolines; Humans; Infusion Pumps; Levodopa; Lisuride; Middle Aged; Movement Disorders; Parkinson Disease | 1990 |
Combination of a dopamine agonist, MAO-B inhibitor and levodopa--a new strategy in the treatment of early Parkinson's disease.
Topics: Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Phenethylamines; Selegiline | 1989 |
Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Ergolines; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Quinpirole | 1989 |
One year treatment with lisuride delivery pump in Parkinson's disease.
Topics: Adult; Drug Therapy, Combination; Ergolines; Female; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1989 |
Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Dose-Response Relationship, Drug; Ergolines; Injections, Intravenous; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Quinpirole; Stereotyped Behavior | 1989 |
Lisuride infusion pump for Parkinson's disease.
Topics: Adult; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Ergolines; Female; Humans; Infusions, Parenteral; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1986 |
Psychosis and the lisuride pump.
Topics: Drug Therapy, Combination; Ergolines; Humans; Infusions, Parenteral; Levodopa; Lisuride; Parkinson Disease; Psychoses, Substance-Induced | 1986 |
Comparative efficacy of two dopamine agonists, pergolide and lergotrile, in Parkinson disease.
Topics: Adult; Aged; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Retrospective Studies | 1988 |
Treatment of Parkinson's disease with subcutaneous lisuride infusions.
Topics: Aged; Drug Eruptions; Drug Therapy, Combination; Ergolines; Female; Hematoma; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Mental Disorders; Middle Aged; Movement Disorders; Parkinson Disease | 1988 |
Lisuride infusion pump in Parkinson's disease. A report of two cases.
Topics: Aged; Drug Administration Schedule; Drug Eruptions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Lisuride; Mental Disorders; Parkinson Disease | 1988 |
Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Basal Ganglia; Benzazepines; Corpus Striatum; Denervation; Dextroamphetamine; Ergolines; Female; Flunarizine; Functional Laterality; Haloperidol; Levodopa; Neural Pathways; Parkinson Disease; Quinpirole; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Substantia Nigra | 1988 |
Dopamine agonists as primary treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Bromocriptine; Disability Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Long-Term Care; Parkinson Disease; Pergolide; Receptors, Dopamine | 1987 |
[Lisuride in the combination treatment of Parkinson disease].
Topics: Adult; Aged; Aged, 80 and over; Carboxy-Lyases; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Long-Term Care; Male; Middle Aged; Parkinson Disease | 1987 |
[Clinical study of pergolide in Parkinson's disease].
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease; Pergolide | 1985 |
Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration.
Topics: Administration, Oral; Adult; Drug Therapy, Combination; Ergolines; Female; Humans; Infusion Pumps; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Time Factors | 1988 |
Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
Topics: Adult; Drug Administration Schedule; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Motor Skills; Parkinson Disease | 1988 |
Continuous dopaminergic stimulation in the management of complicated Parkinson's disease.
Topics: Adult; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1988 |
Lisuride in Parkinson's disease. 4-year follow-up.
Topics: Adult; Aged; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Time Factors | 1988 |
Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
Topics: Administration, Oral; Adult; Aged; Carbidopa; Domperidone; Ergolines; Female; Humans; Infusions, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1986 |
Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Brain; Disease Models, Animal; Ergolines; Levodopa; Lisuride; Male; Motor Activity; Parkinson Disease; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior | 1987 |
Low dose lisuride in advanced Parkinson disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Follow-Up Studies; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1987 |
Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Drug Administration Schedule; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Time Factors | 1986 |
Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
Topics: Adult; Bromocriptine; Carbidopa; Dystonia; Ergolines; Humans; Levodopa; Meige Syndrome; Middle Aged; Parkinson Disease; Pergolide; Torticollis | 1986 |
Transdihydrolisuride in parkinsonism.
Topics: Aged; Blood Pressure; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Movement Disorders; Nausea; Parkinson Disease; Psychoses, Substance-Induced | 1987 |
Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Motor Skills; Parkinson Disease | 1987 |
Practical therapeutics: advances in the management of Parkinson's disease.
Topics: Ergolines; Humans; Levodopa; Parasympatholytics; Parkinson Disease; Phenethylamines; Selegiline | 1985 |
Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; Benzazepines; Dihydroxyphenylalanine; Drug Interactions; Ergolines; Female; Flupenthixol; Haloperidol; Hydroxydopamines; Levodopa; Male; Motor Activity; Oxidopamine; Pregnancy; Quinpirole; Rats; Receptors, Dopamine; Self Mutilation; Stereotyped Behavior | 1985 |
Dopamine agonists suppress visual-cortical reflex myoclonus.
Topics: Aged; Apomorphine; Atrophy; Carbidopa; Cerebellum; Drug Therapy, Combination; Electromyography; Epilepsies, Myoclonic; Ergolines; Evoked Potentials, Somatosensory; Evoked Potentials, Visual; Female; Humans; Levodopa; Lisuride; Olivary Nucleus; Photic Stimulation; Pons; Reflex; Visual Cortex | 1985 |
Lisuride in the treatment of myoclonus.
Topics: Adolescent; Adult; Aged; Carbidopa; Dopamine Antagonists; Electric Stimulation; Electroencephalography; Electromyography; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Myoclonus; Serotonin Antagonists | 1986 |
Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease.
Topics: Adult; Aged; Domperidone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Injections, Intravenous; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1986 |
Efficacy of pergolide and mesulergine.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide | 1986 |
[Dopaminergic agonists in Parkinson disease].
Topics: Aged; Bromocriptine; Dopamine; Ergolines; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; Piribedil | 1986 |
Long-term study of pergolide in Parkinson's disease.
Topics: Adult; Aged; Disability Evaluation; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1985 |
Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
Topics: Aged; Carbidopa; Drug Combinations; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Receptors, Dopamine; Sleep Wake Disorders; Sleep, REM | 1985 |
Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Dystonia; Ergolines; Female; Hallucinations; Humans; Levodopa; Male; Middle Aged; Nausea; Outcome and Process Assessment, Health Care; Parkinson Disease; Pergolide; Time Factors | 1985 |
Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
Topics: Adult; Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1985 |
Effects of lisuride on blink reflex habituation in Parkinson disease.
Topics: Adult; Aged; Amantadine; Blinking; Electrophysiology; Ergolines; Habituation, Psychophysiologic; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1985 |
[Oral lisuride in Parkinson's disease].
Topics: Adult; Aged; Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1985 |
Treatment of parkinsonism with bromocriptine.
Topics: Bromocriptine; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Parkinson Disease | 1974 |
Dopamine agonists and Parkinson's disease.
Topics: Antiparkinson Agents; Apomorphine; Brain; Bromocriptine; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Neurons; Parkinson Disease; Pergolide; Piribedil; Receptors, Dopamine | 1984 |
Cross tolerance between two dopaminergic ergot derivatives--bromocriptine and lergotrile.
Topics: Aged; Blood Pressure; Bromocriptine; Drug Tolerance; Ergolines; Heart Rate; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1980 |
Akinetic mutism from hypothalamic damage: successful treatment with dopamine agonists.
Topics: Adult; Akinetic Mutism; Bromocriptine; Carbidopa; Ergolines; Humans; Hypothalamic Neoplasms; Hypothalamus; Levodopa; Male; Methylphenidate; Postoperative Complications | 1981 |
Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon.
Topics: Antiparkinson Agents; Bromocriptine; Carbidopa; Ergolines; Female; gamma-Aminobutyric Acid; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prognosis; Radioligand Assay | 1982 |
Therapeutic experience with the new dopamine agonist CU 32-085 in advanced Parkinson's disease.
Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parasympatholytics; Parkinson Disease | 1983 |
Dopamine agonists in Parkinson's disease.
Topics: Bromocriptine; Dopamine; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Humans; Levodopa; Lisuride; Parkinson Disease; Pergolide; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1984 |
Dopamine agonists in the treatment of Parkinson's disease.
Topics: Blood Pressure; Bromocriptine; Disability Evaluation; Domperidone; Dopamine; Ergolines; Follow-Up Studies; Humans; Levodopa; Parkinson Disease; Pleural Effusion; Receptors, Neurotransmitter; Time Factors | 1983 |
Drug treatment in Parkinson's disease.
Topics: Antiparkinson Agents; Ergolines; Humans; Levodopa; Parasympatholytics; Parkinson Disease | 1984 |
Treatment of dyskinetic and dystonic disorders with CF 25-397: clinical and pharmacological aspects.
Topics: Aged; Carbidopa; Dystonia; Ergolines; Female; Hepatolenticular Degeneration; Humans; Huntington Disease; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease | 1980 |
Pergolide therapy in Parkinson's disease.
Topics: Aged; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Long-term treatment with pergolide: decreased efficacy with time.
Topics: Aged; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1984 |
Pergolide in the treatment of Parkinson's disease.
Topics: Adult; Aged; Carbidopa; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum.
Topics: Animals; Corpus Striatum; Denervation; Ergolines; Levodopa; Male; Parkinson Disease; Pergolide; Rats; Rats, Inbred Strains; Receptors, Dopamine | 1984 |
Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
Topics: Activities of Daily Living; Adult; Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Ergolines; Female; Humans; Hypotension, Orthostatic; Levodopa; Male; Middle Aged; Nausea; Parkinson Disease; Psychomotor Performance; Receptors, Dopamine | 1983 |
Pergolide in the treatment of Parkinson's disease.
Topics: Antiparkinson Agents; Domperidone; Ergolines; Humans; Levodopa; Mental Disorders; Parkinson Disease; Parkinson Disease, Postencephalitic; Pergolide | 1984 |
Therapeutic results with a new ergoline derivate (8-alpha-amino-ergoline, CU 32-085) in parkinsonian patients.
Topics: Aged; Antiparkinson Agents; Bromocriptine; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease | 1984 |
Bromocriptine and lisuride in Parkinson's disease.
Topics: Adult; Aged; Bromocriptine; Carboxy-Lyases; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1984 |
One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
Topics: Athetosis; Carbidopa; Chorea; Drug Combinations; Drug Evaluation; Drug Therapy, Combination; Ergolines; Humans; Hypotension; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1984 |
Bromocriptine and lisuride in Parkinson disease.
Topics: Aged; Bromocriptine; Carbidopa; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1983 |
[Effect of lisuride in the "on-off" phenomena due to L-dopa].
Topics: Aged; Antiparkinson Agents; Drug Evaluation; Drug Resistance; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease | 1983 |
Pergolide treatment in parkinsonism.
Topics: Adult; Aged; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Respiration Disorders | 1983 |
Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease.
Topics: Aged; Bromocriptine; Disability Evaluation; Drug Evaluation; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Pergolide; Time Factors | 1983 |
Pergolide mesylate and idiopathic Parkinson disease.
Topics: Adolescent; Adult; Carbidopa; Child; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 1982 |
Further studies with pergolide in Parkinson disease.
Topics: Adult; Aged; Carbidopa; Confusion; Drug Combinations; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 1982 |
Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist.
Topics: Aged; Ergolines; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced | 1981 |
Pergolide mesylate: new therapy for Parkinson disease.
Topics: Antiparkinson Agents; Arrhythmias, Cardiac; Ergolines; Humans; Levodopa; Parkinson Disease; Pergolide | 1982 |
The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Double-Blind Method; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Random Allocation; Time Factors | 1982 |
Treatment of advanced Parkinson disease with pergolide.
Topics: Aged; Arrhythmias, Cardiac; Brain; Dopamine; Double-Blind Method; Ergolines; Humans; Levodopa; Middle Aged; Neurons; Parkinson Disease; Pergolide; Random Allocation | 1981 |
Cardiac effects of pergolide.
Topics: Aged; Antiparkinson Agents; Arrhythmias, Cardiac; Carbidopa; Drug Therapy, Combination; Ergolines; Heart; Heart Rate; Humans; Levodopa; Middle Aged; Pergolide | 1981 |
Lisuride in the treatment of Parkinsonism.
Topics: Administration, Oral; Aged; Bromocriptine; Drug Therapy, Combination; Ergolines; Humans; Injections, Intravenous; Levodopa; Lisuride; Middle Aged; Parkinson Disease | 1980 |
Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphine; Brain Tissue Transplantation; Carbidopa; Dextroamphetamine; Disease Models, Animal; Dopamine; Dopamine Agonists; Ergolines; Female; Fetal Tissue Transplantation; Forelimb; Functional Laterality; Levodopa; Motor Activity; Movement Disorders; Norepinephrine; Oxidopamine; Parkinson Disease; Quinpirole; Rats; Rats, Sprague-Dawley; Rotation; Substantia Nigra; Transplantation, Heterotopic | 1995 |
Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa.
Topics: Animals; Benzopyrans; Corpus Striatum; Dopamine Agonists; Ergolines; Genes, fos; Immunohistochemistry; Levodopa; Male; Quinpirole; Rats; Rats, Sprague-Dawley | 1995 |
Drenching sweats as an off phenomenon in Parkinson's disease: treatment and relation to plasma levodopa profile.
Topics: Aged; Bromocriptine; Cabergoline; Chorea; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Monitoring, Physiologic; Parkinson Disease; Pergolide; Sweating | 1995 |
Dopamine receptor agonists and antagonists both inhibit dopamine secretion in LLC-PK1 cells.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benzazepines; Cell Line; Chlorpromazine; Chromatography, High Pressure Liquid; Dopamine; Dopamine Agents; Dopamine Antagonists; Epithelial Cells; Epithelium; Ergolines; Fenoldopam; Kidney; Levodopa; Phenothiazines; Quinpirole; Trifluoperazine | 1993 |
Cabergoline in Parkinson's disease: long-term follow-up.
Topics: Adult; Aged; Cabergoline; Dopamine Agents; Drug Therapy, Combination; Ergolines; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 1993 |
Adenosine A2 receptors interact negatively with dopamine D1 and D2 receptors in unilaterally 6-hydroxydopamine-lesioned rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adenosine; Animals; Antihypertensive Agents; Autoradiography; Basal Ganglia; Benserazide; Binding Sites; Dopamine Agents; Ergolines; Levodopa; Male; Neural Pathways; Neurons; Oxidopamine; Phenethylamines; Quinolinic Acid; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Purinergic P1; Stereotyped Behavior | 1994 |
The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Benzodiazepines; Catalepsy; Dizocilpine Maleate; Drug Interactions; Ergolines; Haloperidol; Levodopa; Male; Pilot Projects; Quinoxalines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 1994 |
Non-effective dose of exogenously applied L-dopa itself stereoselectively potentiates postsynaptic D2 receptor-mediated locomotor activities of conscious rats.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Desipramine; Dopamine Agents; Ergolines; Hydrazines; Injections, Intraventricular; Levodopa; Male; Microdialysis; Motor Activity; Nerve Fibers; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereoisomerism | 1994 |
6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Calcium-Calmodulin-Dependent Protein Kinases; Cells, Cultured; Corpus Striatum; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Dopamine; Embryo, Mammalian; Ergolines; Gene Expression; Genes, fos; Levodopa; Male; Neurons; Oxidopamine; Phosphorylation; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Salicylamides; Substantia Nigra | 1994 |
MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Benzazepines; Dizocilpine Maleate; Dopamine Agents; Dopamine Agonists; Ergolines; Excitatory Amino Acid Antagonists; Levodopa; Male; Oxidopamine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Stereotyped Behavior; Sympatholytics | 1995 |
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Brain; Cabergoline; Carbidopa; Diabetes Mellitus; Ergolines; Female; Free Radicals; Humans; Levodopa; Lipid Peroxidation; Male; Malondialdehyde; Oxidative Stress; Parkinson Disease; Selegiline; Vitamin E | 1995 |
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats.
Topics: Acetylcholine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Synergism; Ergolines; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Quinpirole; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes | 1995 |
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Topics: Analysis of Variance; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Treatment Outcome | 1995 |
Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents.
Topics: Animals; Cabergoline; Dopamine Agonists; Ergolines; Levodopa; Male; Mice; Motor Activity; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Reserpine | 1996 |
Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Hyperkinesis; Levodopa; Macaca fascicularis; Movement; Parkinson Disease, Secondary | 1996 |
A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Benzothiazoles; Cabergoline; Disorders of Excessive Somnolence; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pramipexole; Retrospective Studies; Thiazoles | 2001 |
Efficacy and tolerability of dopamine agonists in a parkinsonian population.
Topics: Age of Onset; Aged; Aging; Benzothiazoles; Bromocriptine; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Ergolines; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Retrospective Studies; Thiazoles; Treatment Outcome | 2001 |
Effects of short- and long-acting dopamine agonists on sensitized dopaminergic neurotransmission in rats with unilateral 6-OHDA lesions.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Cabergoline; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Antagonism; Ergolines; Levodopa; Male; Oxidopamine; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Synaptic Transmission | 2002 |
Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment.
Topics: Aged; Brain; Cabergoline; Delta Rhythm; Dopamine Agonists; Drug Therapy, Combination; Electroencephalography; Electromyography; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep, REM; Wakefulness | 2002 |
Determination of cabergoline and L-dopa in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Adult; Cabergoline; Case-Control Studies; Chromatography, Liquid; Dopamine Agonists; Ergolines; Humans; Levodopa; Middle Aged; Reproducibility of Results; Schizophrenia; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
[Three patients with Parkinson's disease whose therapeutic levels were successfully improved after administration of quetiapine for suppression of psychosis].
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cabergoline; Dibenzothiazepines; Ergolines; Hallucinations; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychoses, Substance-Induced; Quetiapine Fumarate | 2003 |
Cabergoline versus levodopa monotherapy: a decision analysis.
Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Making; Disease Progression; Ergolines; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; Severity of Illness Index | 2003 |
Improvement of sleep hypopnea by antiparkinsonian drugs in a patient with Parkinson's disease: a polysomnographic study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Benserazide; Cabergoline; Ergolines; Humans; Levodopa; Male; Parkinson Disease; Polysomnography; Sleep Apnea Syndromes | 2003 |
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
Topics: Adult; Aged; Cabergoline; Carbidopa; Dopamine Agonists; Drug Combinations; Echocardiography, Transesophageal; Ergolines; Ergot Alkaloids; Female; Heart Valve Diseases; Humans; Levodopa; Male; Parkinson Disease; Pergolide | 2004 |
Cabergoline versus levodopa monotherapy.
Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease | 2004 |
Re: Cabergoline versus levodopa monotherapy: a decision analysis.
Topics: Age Factors; Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Support Techniques; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Prospective Studies; Surveys and Questionnaires | 2004 |
Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Antiparkinson Agents; Benzothiazoles; Bromocriptine; Cabergoline; Domperidone; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ergolines; Ergot Alkaloids; Feasibility Studies; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide; Pramipexole; Therapeutic Equivalency; Thiazoles | 2004 |
Predictors of sudden onset of sleep in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Comorbidity; Cross-Sectional Studies; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Narcolepsy; Parkinson Disease; Pramipexole; Risk Factors; Surveys and Questionnaires; Thiazoles | 2004 |
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Cabergoline; Carbidopa; Caspases; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; Drug Combinations; Drug Interactions; Enzyme Activation; Ergolines; Glutathione; Homovanillic Acid; Levodopa; Male; Mice; Mice, Inbred ICR; Neurotoxicity Syndromes; Oxidopamine; Thiobarbituric Acid Reactive Substances | 2005 |
Psychiatric sequelae of Parkinson disease: a case report.
Topics: Antiparkinson Agents; Cabergoline; Carbidopa; Compulsive Behavior; Drug Combinations; Ergolines; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Offenses | 2006 |
Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Cabergoline; Chromatography, High Pressure Liquid; Ergolines; Female; Free Radical Scavengers; Humans; Levodopa; Male; Oxidative Stress; Parkinson Disease; Peroxynitrous Acid; Tyrosine | 2006 |
Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
Topics: Aged; Antiparkinson Agents; Cabergoline; Circadian Rhythm; Ergolines; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Polysomnography; Sleep; Wakefulness | 2006 |
[Case of juvenile parkinsonism in pregnancy].
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Contraindications; Dopamine Agents; Dopamine Agonists; Ergolines; Family Planning Services; Female; Humans; Infant, Newborn; Levodopa; Parkinsonian Disorders; Pramipexole; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Thiazoles | 2006 |
[Association between amytrophic lateral sclerosis and Parkinson's disease].
Topics: Aged; Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Cabergoline; Carbidopa; Dopamine Agents; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Riluzole; Time Factors; Tomography, X-Ray Computed | 2007 |
Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.
Topics: Amino Acids; Animals; Antiparkinson Agents; Autoradiography; Basal Ganglia; Behavior, Animal; Cabergoline; Caudate Nucleus; Data Interpretation, Statistical; Dyskinesia, Drug-Induced; Ergolines; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Ovariectomy; Putamen; Receptors, Metabotropic Glutamate; Xanthenes | 2008 |
Emotional speech in Parkinson's disease.
Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Cabergoline; Emotions; Ergolines; Humans; Levodopa; Middle Aged; Parkinson Disease; Phonation; Speech | 2008 |
Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
Topics: Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Benzothiazoles; Cabergoline; Disease Models, Animal; Dopamine Antagonists; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Levodopa; Mesencephalon; Oxidopamine; Parkinsonian Disorders; Pramipexole; Rats; Rats, Wistar; Stereotyped Behavior; Tyrosine 3-Monooxygenase | 2008 |
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Autoradiography; Behavior, Animal; Benserazide; Benzoxazoles; Cabergoline; Corpus Striatum; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dyskinesias; Ergolines; Female; Humans; Levodopa; Macaca fascicularis; MPTP Poisoning; Ovariectomy; Piperidines; Receptors, Glutamate; Receptors, N-Methyl-D-Aspartate | 2009 |
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.
Topics: Aged; Antiparkinson Agents; Azepines; Benzothiazoles; Cabergoline; Carbidopa; Catatonia; Catechols; Drug Therapy, Combination; Electroconvulsive Therapy; Ergolines; Female; Humans; Levodopa; Nitriles; Parkinson Disease; Pramipexole | 2009 |
Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity.
Topics: Antiparkinson Agents; Arm; Art; Benzothiazoles; Brain; Cabergoline; Creativity; Depressive Disorder; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ergolines; Humans; Levodopa; Male; Mental Disorders; Middle Aged; Motor Skills; Obsessive Behavior; Paintings; Parkinson Disease; Pramipexole | 2009 |
Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.
Topics: Animals; Antiparkinson Agents; Benzoxazoles; Cabergoline; Corpus Striatum; Disease Models, Animal; Drug Interactions; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Ergolines; Female; Glycogen Synthase Kinase 3; Levodopa; Macaca fascicularis; Oncogene Protein v-akt; Parkinsonian Disorders; Phosphorylation; Piperidines; Serine; Signal Transduction; Statistics as Topic | 2010 |
Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.
Topics: Animals; Antiparkinson Agents; Autoradiography; Benzoxazoles; Brain; Cabergoline; Drug Interactions; Dyskinesia, Drug-Induced; Ergolines; Female; Imidazoles; Levodopa; Ligands; Macaca fascicularis; MPTP Poisoning; Piperidines; Quinazolines; Receptors, AMPA; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate | 2010 |
Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Biogenic Amines; Brain; Cabergoline; Dopamine Agents; Dyskinesia, Drug-Induced; Ergolines; Female; Humans; Ketanserin; Levodopa; Macaca; Parkinsonian Disorders; Receptor, Serotonin, 5-HT2A | 2011 |
Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain Ischemia; Case-Control Studies; Databases, Factual; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Hospitalization; Humans; Ischemia; Levodopa; Male; Myocardial Ischemia; Netherlands; Parkinson Disease; Practice Patterns, Physicians'; Prevalence; Raynaud Disease; Severity of Illness Index | 2012 |
Selective IGT decision-making impairment in a patient with juvenile Parkinson's disease and pathological gambling: a role for dopaminergic therapy?
Topics: Adult; Antiparkinson Agents; Benzothiazoles; Cabergoline; Case-Control Studies; Compulsive Behavior; Decision Making; Dopamine Agonists; Drug Therapy, Combination; Ergolines; Female; Gambling; Humans; Levodopa; Matched-Pair Analysis; Neuropsychological Tests; Parkinsonian Disorders; Pramipexole; Reference Values | 2012 |
Finasteride attenuates pathological gambling in patients with Parkinson disease.
Topics: 5-alpha Reductase Inhibitors; Aged; Antiparkinson Agents; Benzothiazoles; Cabergoline; Carbidopa; Catechols; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Ergolines; Finasteride; Gambling; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Pramipexole; Treatment Outcome; Video Games | 2012 |
'You never told me I would turn into a gambler': a first person account of dopamine agonist--induced gambling addiction in a patient with restless legs syndrome.
Topics: Cabergoline; Carbidopa; Cognitive Behavioral Therapy; Dopamine Agonists; Drug Combinations; Ergolines; Gambling; Humans; Indoles; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Tetrahydronaphthalenes; Thiophenes | 2011 |
Occlusal treatment with bite splint improves dyskinesia in Parkinson's disease patient: a case report.
Topics: Activities of Daily Living; Antiparkinson Agents; Bromocriptine; Cabergoline; Clonidine; Dyskinesias; Ergolines; Female; Hand Strength; Humans; Levodopa; Middle Aged; Motor Skills; Occlusal Splints; Parkinson Disease; Posture | 2013 |
Prescribing pattern of anti-Parkinson drugs in Japan: a trend analysis from 2005 to 2010.
Topics: Aged; Antiparkinson Agents; Cabergoline; Dopamine Agonists; Drug Prescriptions; Ergolines; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide | 2014 |